4+ hour, 3+ min ago  (206+ words) Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on Linked In: "ASCO26 | Metastatic Breast Cancer Oral Session " Key Takeaways The recurring question: when 1 L data are positive, does benefit carry downstream? Several PFS2 analyses said…...

22+ hour ago  (878+ words) The phase III JCOG1919 E AMBITION trial, presented by Fumikata Hara at the 2026 ASCO Annual Meeting, evaluated whether adding atezolizumab to paclitaxel plus bevacizumab could improve outcomes in patients with hormone receptor-positive/HER2-negative advanced breast cancer (Hara et al. , 2026). Immune checkpoint…...

2+ day, 17+ hour ago  (94+ words) Elvina Almuradova: Treatment Landscape for HR+/HER2" Metastatic Breast Cancer Is Evolving Rapidly Oncodaily Elvina Almuradova: Treatment Landscape for HR+/HER2" Metastatic Breast Cancer Is Evolving Rapidly Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post…...

3+ day, 1+ hour ago  (197+ words) Armando Orlandi, Medical Director at the Agostino Gemelli University Hospital Foundation IRCCS, shared a post on Linked In: "ASCO26 | Early & Adjuvant Breast Cancer Rapid Oral Session " Key Takeaways Two directions at once: peeling back treatment intensity where outcomes allow, and investing…...

5+ day, 31+ min ago  (132+ words) Chairing and Presenting at ASCO26: "Navigating HR+ Metastatic Breast Cancer Honored to have chaired and presented at the 2026 ASCO Annual Meeting in Chicago yesterday, with a packed Hall D1, a sign of just how pressing this topic is for the oncology community....

5+ day, 12+ min ago  (86+ words) Onco Daily is a specialized news and information platform that provides daily updates on oncology research, treatments, clinical trials, and advancements in cancer care. It serves healthcare professionals, researchers, and patients by delivering timely and accurate insights into the latest…...

5+ day, 25+ min ago  (75+ words) Sakditad Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, shared a post on X: "Congratulations to Chalothorn Wannaphut on presenting this important work at ASCO26! Poster 567 highlights how ZIP-code " level socioeconomic distress predicts advanced-stage diagnosis and mortality among women with breast cancer…...

6+ day, 17+ hour ago  (70+ words) Ilana Schlam, Breast medical oncologist at Dana-Farber Cancer Institute, shared a post on'X: "Happy to share our review on ct DNA in early breast cancer. We discuss current evidence, clinical applications, challenges, and future directions." Authors: Ilana Schlam, Sara M. Tolaney,…...

1+ week, 1+ hour ago  (136+ words) Chadi Nabhan, hematologist and medical oncologist, Chief Medical Officer and Head of Strategy at Ryght, shared a post on Linked In: "Just as we all head to the annual ASCO26 meeting in Chicago, I am proud to share that the American…...

1+ week, 10+ hour ago  (674+ words) This finding matters because HR+/HER2+ breast cancer sits at the intersection of two therapeutic worlds: endocrine sensitivity and HER2 dependency. The clinical question is not simply whether chemotherapy can produce deeper early tumor eradication, but whether selected patients can achieve durable…...